Exelixis, Inc. (EXEL)Healthcare | Biotechnology | Alameda, United States | NasdaqGS
56.04 USD
-0.46
(-0.814%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 2:54 a.m. EDT
The investment case here is built on a powerful convergence of explosive recent performance and pristine fundamentals. The stock has delivered a staggering +98.9% return over the last year, pushing the nine-year cumulative gain to +450%, yet the company remains undervalued relative to its growth profile with a forward P/E of just 14x and robust 41% operating margins. While the lack of a dividend is a non-issue for this high-growth biotech, the balance sheet is fortress-like with $777M in cash against minimal debt. Short-term momentum is building rapidly; the price has climbed from the $51 range to $57 over the past two weeks, supported by heavy speculative call buying targeting the $60 level. This options flow confirms that smart money is betting on further upside, likely driven by the positive clinical trial results mentioned in recent headlines. The statistical forecast model offers only a weak lean, which is typical for such volatile assets, but it does not contradict the overwhelming evidence of strength found in the fundamentals and options data. This is a high-conviction entry for investors seeking exposure to a biotech powerhouse with a proven track record of delivering. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.096664 |
| MSTL | 0.112013 |
| AutoETS | 0.118861 |
| AutoARIMA | 0.120561 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 3.58 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.011 |
| Excess Kurtosis | 0.27 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 8.758 |
| Revenue per Share | 8.915 |
| Market Cap | 14,085,939,200 |
| Trailing P/E | 18.56 |
| Forward P/E | 14.03 |
| Beta | 0.42 |
| Profit Margins | 35.08% |
| Website | https://www.exelixis.com |
As of July 11, 2026, 2:54 a.m. EDT: Speculators are aggressively positioning for upside, evidenced by massive open interest in out-of-the-money calls (e.g., 2.7k contracts at the $60 strike for July expiration) compared to negligible put volume. The call chain shows a distinct 'top OI' at strikes significantly above the current price, while the put side is nearly empty except for deep out-of-the-money hedges. Implied volatility remains moderate (~50%), suggesting the market expects continued appreciation without a looming crash event.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.23957872 |
| Address1 | 1,851 Harbor Bay Parkway |
| All Time High | 57.57 |
| All Time Low | 1.26 |
| Ask | 58.23 |
| Ask Size | 1 |
| Audit Risk | 5 |
| Average Analyst Rating | 2.3 - Buy |
| Average Daily Volume10 Day | 3,031,830 |
| Average Daily Volume3 Month | 2,742,468 |
| Average Volume | 2,742,468 |
| Average Volume10Days | 3,031,830 |
| Beta | 0.424 |
| Bid | 52.86 |
| Bid Size | 1 |
| Board Risk | 1 |
| Book Value | 7.63 |
| City | Alameda |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 4 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 56.04 |
| Current Ratio | 3.258 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 56.465 |
| Day Low | 55.08 |
| Debt To Equity | 8.758 |
| Display Name | Exelixis |
| Earnings Call Timestamp End | 1,778,014,800 |
| Earnings Call Timestamp Start | 1,778,014,800 |
| Earnings Growth | 0.436 |
| Earnings Quarterly Growth | 0.319 |
| Earnings Timestamp | 1,778,011,200 |
| Earnings Timestamp End | 1,785,873,600 |
| Earnings Timestamp Start | 1,785,873,600 |
| Ebitda | 985,841,024 |
| Ebitda Margins | 0.41501 |
| Enterprise To Ebitda | 13.672 |
| Enterprise To Revenue | 5.674 |
| Enterprise Value | 13,478,273,024 |
| Eps Current Year | 3.52636 |
| Eps Forward | 3.99455 |
| Eps Trailing Twelve Months | 3.02 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 650 837 8300 |
| Fifty Day Average | 51.1942 |
| Fifty Day Average Change | 4.8458023 |
| Fifty Day Average Change Percent | 0.094655305 |
| Fifty Two Week Change Percent | 23.957872 |
| Fifty Two Week High | 57.57 |
| Fifty Two Week High Change | -1.5299988 |
| Fifty Two Week High Change Percent | -0.026576322 |
| Fifty Two Week Low | 33.76 |
| Fifty Two Week Low Change | 22.280003 |
| Fifty Two Week Low Change Percent | 0.6599527 |
| Fifty Two Week Range | 33.76 - 57.57 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 955,978,200,000 |
| Float Shares | 204,464,792 |
| Forward Eps | 3.99455 |
| Forward P E | 14.029115 |
| Free Cashflow | 629,119,360 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 1,077 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.96444 |
| Gross Profits | 2,291,013,120 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01821 |
| Held Percent Institutions | 1.06831 |
| Implied Shares Outstanding | 251,355,083 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.exelixis.com/investors-media |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California. |
| Long Name | Exelixis, Inc. |
| Market | us_market |
| Market Cap | 14,085,939,200 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_28338 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 833,420,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 14,202,818,964 |
| Number Of Analyst Opinions | 16 |
| Open | 56.24 |
| Operating Cashflow | 924,675,008 |
| Operating Margins | 0.41149 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Peg Ratio | 2.56 |
| Phone | 650 837 7000 |
| Pre Market Change | -0.3199997 |
| Pre Market Change Percent | -0.5710201 |
| Pre Market Price | 55.72 |
| Pre Market Time | 1,784,025,646 |
| Previous Close | 56.5 |
| Price Eps Current Year | 15.891741 |
| Price Hint | 2 |
| Price To Book | 7.344692 |
| Price To Sales Trailing12 Months | 5.9296956 |
| Profit Margins | 0.35084 |
| Quick Ratio | 3.01 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.26316 |
| Region | US |
| Regular Market Change | -0.459999 |
| Regular Market Change Percent | -0.814158 |
| Regular Market Day High | 56.465 |
| Regular Market Day Low | 55.08 |
| Regular Market Day Range | 55.08 - 56.465 |
| Regular Market Open | 56.24 |
| Regular Market Previous Close | 56.5 |
| Regular Market Price | 56.04 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 2,539,569 |
| Return On Assets | 0.22031 |
| Return On Equity | 0.40987 |
| Revenue Growth | 0.1 |
| Revenue Per Share | 8.915 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 251,355,083 |
| Shares Percent Shares Out | 0.11350001 |
| Shares Short | 28,539,118 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 29,707,071 |
| Short Name | Exelixis, Inc. |
| Short Percent Of Float | 0.15439999 |
| Short Ratio | 10.18 |
| Source Interval | 15 |
| State | CA |
| Symbol | EXEL |
| Target High Price | 62.0 |
| Target Low Price | 41.0 |
| Target Mean Price | 50.9375 |
| Target Median Price | 51.0 |
| Total Cash | 777,206,976 |
| Total Cash Per Share | 3.092 |
| Total Debt | 169,540,992 |
| Total Revenue | 2,375,491,072 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 3.02 |
| Trailing P E | 18.556292 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 44.5956 |
| Two Hundred Day Average Change | 11.444401 |
| Two Hundred Day Average Change Percent | 0.25662622 |
| Type Disp | Equity |
| Volume | 2,539,569 |
| Website | https://www.exelixis.com |
| Zip | 94,502 |